Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Palanichamy Ilankumaran

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Journal of Organic Chemistry|October 25, 2001
P(RNCH(2)CH(2))(3)N: Efficient Catalysts for Transesterifications, Acylations, and DeacylationsPalanichamy Ilankumaran, J. G. Verkade
The Journal of Organic Chemistry|May 25, 2002
P(RNCH(2)CH(2))(3)N: efficient 1,4-addition catalystsPhilip B Kisanga, Palanichamy Ilankumaran, Brandon M Fetterly, et al.
Clinical Pharmacology in Drug Development|June 23, 2022
Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room TemperatureEugene Y Tan, Ovidiu Chiparus, Somesh Choudhury, et al.
Clinical Pharmacology in Drug Development|February 14, 2022
Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid TumorsHendrik-Tobias Arkenau, Donatienne Taylor, Xiaoying Xu, et al.
The EMBO Journal|November 29, 2002
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNAStefan G Sarafianos, Arthur D Clark, Kalyan Das, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2020
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaLu Si, Xiaoshi Zhang, Sang Joon Shin, et al.
The Journal of Biological Chemistry|January 30, 2003
Trapping HIV-1 reverse transcriptase before and after translocation on DNAStefan G Sarafianos, Arthur D Clark, Steve Tuske, et al.
Blood|September 15, 2022
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemiaRobert J Kreitman, Philippe Moreau, Farhad Ravandi, et al.
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Journal of Organic Chemistry|October 25, 2001
P(RNCH(2)CH(2))(3)N: Efficient Catalysts for Transesterifications, Acylations, and DeacylationsPalanichamy Ilankumaran, J. G. Verkade
The Journal of Organic Chemistry|May 25, 2002
P(RNCH(2)CH(2))(3)N: efficient 1,4-addition catalystsPhilip B Kisanga, Palanichamy Ilankumaran, Brandon M Fetterly, et al.
Clinical Pharmacology in Drug Development|June 23, 2022
Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room TemperatureEugene Y Tan, Ovidiu Chiparus, Somesh Choudhury, et al.
Clinical Pharmacology in Drug Development|February 14, 2022
Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid TumorsHendrik-Tobias Arkenau, Donatienne Taylor, Xiaoying Xu, et al.
The EMBO Journal|November 29, 2002
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNAStefan G Sarafianos, Arthur D Clark, Kalyan Das, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2020
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaLu Si, Xiaoshi Zhang, Sang Joon Shin, et al.
The Journal of Biological Chemistry|January 30, 2003
Trapping HIV-1 reverse transcriptase before and after translocation on DNAStefan G Sarafianos, Arthur D Clark, Steve Tuske, et al.
Blood|September 15, 2022
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemiaRobert J Kreitman, Philippe Moreau, Farhad Ravandi, et al.
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
Nature Medicine|April 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trialVivek Subbiah, Robert J Kreitman, Zev A Wainberg, et al.
Pageof 2